홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

PF-06454589 → HCID 72706903, 화합물

HRID 1750290
인쇄

반응식

HRID 1750290 반응식
[CH3:1][C:2]1[N:3]=[C:4]([N:27]2[CH2:32][CH2:31][O:30][CH2:29][CH2:28]2)[C:5]2[C:10]([C:11]3[CH:12]=[C:13]([CH:16]=[CH:17][CH:18]=3)[C:14]#[N:15])=[CH:9][N:8](COCC[Si](C)(C)C)[C:6]=2[N:7]=1.CN1C=C(C2C3C(N4CCOCC4)=NC=NC=3NC=2)C=N1>>[CH3:1][C:2]1[N:3]=[C:4]([N:27]2[CH2:32][CH2:31][O:30][CH2:29][CH2:28]2)[C:5]2[C:10]([C:11]3[CH:12]=[C:13]([CH:16]=[CH:17][CH:18]=3)[C:14]#[N:15])=[CH:9][NH:8][C:6]=2[N:7]=1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

3

반응물 2

HCID 72706837PF-06454589HCID 86706961HCID 86706961, 화합물

생성물 1

HCID 72706903HCID 72706903, 화합물

실험 절차

3-[2-Methyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (C25) was converted to the product using the method described for synthesis of 5-(1-methyl-1H-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine (1) in Example 1. In this case, preparative HPLC purification was carried out using a Phenomenex Gemini C18 column, 8 μm; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 30% to 50% B. The product was obtained as a white solid. Yield: 17.3 mg, 54.2 μmol, 45% over 2 steps. LCMS m/z 320.1 [M+H+]. 1H NMR (400 MHz, CD3OD) δ 7.91-7.93 (m, 1H), 7.85-7.88 (m, 1H), 7.60-7.69 (m, 2H), 7.38 (s, 1H), 3.51-3.55 (m, 4H), 3.24-3.28 (m, 4H), 2.59 (s, 3H).

후처리

  1. customIn this case, preparative HPLC purification
  • customThe product was obtained as a white solid
  • 출처 및 근거

    ORD 기록
    ord-a6860327f50f441e8003b69a9848e4fc
    출처 데이터셋
    uspto-grants-2015_10
    DOI
    10.6084/m9.figshare.5104873.v1
    특허 번호
    US09156845B2

    반응 노트

    이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트